Qing Cao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Qing Cao has a total of 223 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Jordan Weisdorf
Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, USA
22 shared publications - Shernan G. Holtan
Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
20 shared publications - Armin Rashidi
Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA
19 shared publications - Xianghua Luo
Division of Biostatistics and Health Data Science School of Public Health, University of Minnesota Minneapolis Minnesota USA
19 shared publications - Alexander Khoruts
Department of Medicine, University of Minnesota
18 shared publications - Amanda J. Kabage
University of Minnesota
18 shared publications
Latest Publications
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study
Purpose:This multicenter, single-arm, phase II trial evaluated the safety and efficacy of cabazitaxel and carboplatin followed by abiraterone, plus androgen deprivation therapy (ADT), in patients with high-volume metastatic castration-sensitive prostate cancer (mCSPC).Patients and Methods:Eligible patients had high-volume mCSPC and ≤3 months of prior ADT. Patients received six 21-day cycles of cabazitaxel (20 mg/m2) and carboplatin (AUC 4) with continuous ADT, followed by maintenance abiraterone (1,000 mg daily) and prednisone (5 mg daily). The primary endpoint was the proportion of patients free of prostate-specific antigen (PSA) or radiographic progression at 12 months. Secondary endpoints included complete PSA response (≤0.2 ng/mL), objective response, progression-free survival (PFS), and safety. Overall survival (OS) was also reported.Results:Sixty-one participants were enrolled at eight sites. The median age was 64 years, median baseline PSA was 6.6 ng/mL (0.07–745.7 ng/mL), 73.3% had Gleason grade group 5, 69.5% had 10 or more metastases, and 19.6% had a homologous recombination repair (HRR) mutation. PSA PFS at 12 months was 84.6% [95% confidence interval (CI), 72.5%–91.7%], and OS at 12 months was 94.8% (84.7%–98.3%). Complete PSA response was 66.7%, and complete objective response was 30.7%. Contrary to our hypothesis, relative to HRR wild-type patients, HRR-mutated patients (19.6%) had numerically fewer complete PSA responses (33.3% vs. 70.3%) and inferior PFS (HR, 2.43; 95% CI, 0.93–6.39). Common side effects of this quadruplet regimen included fatigue, nausea, and diarrhea.Conclusions:Cabazitaxel and carboplatin followed by abiraterone, together with ADT, were feasible, safe, and efficacious in patients with high-volume mCSPC and warrant further study in larger randomized trials.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study
Purpose:This multicenter, single-arm, phase II trial evaluated the safety and efficacy of cabazitaxel and carboplatin followed by abiraterone, plus androgen deprivation therapy (ADT), in patients with high-volume metastatic castration-sensitive prostate cancer (mCSPC).Patients and Methods:Eligible patients had high-volume mCSPC and ≤3 months of prior ADT. Patients received six 21-day cycles of cabazitaxel (20 mg/m2) and carboplatin (AUC 4) with continuous ADT, followed by maintenance abiraterone (1,000 mg daily) and prednisone (5 mg daily). The primary endpoint was the proportion of patients free of prostate-specific antigen (PSA) or radiographic progression at 12 months. Secondary endpoints included complete PSA response (≤0.2 ng/mL), objective response, progression-free survival (PFS), and safety. Overall survival (OS) was also reported.Results:Sixty-one participants were enrolled at eight sites. The median age was 64 years, median baseline PSA was 6.6 ng/mL (0.07–745.7 ng/mL), 73.3% had Gleason grade group 5, 69.5% had 10 or more metastases, and 19.6% had a homologous recombination repair (HRR) mutation. PSA PFS at 12 months was 84.6% [95% confidence interval (CI), 72.5%–91.7%], and OS at 12 months was 94.8% (84.7%–98.3%). Complete PSA response was 66.7%, and complete objective response was 30.7%. Contrary to our hypothesis, relative to HRR wild-type patients, HRR-mutated patients (19.6%) had numerically fewer complete PSA responses (33.3% vs. 70.3%) and inferior PFS (HR, 2.43; 95% CI, 0.93–6.39). Common side effects of this quadruplet regimen included fatigue, nausea, and diarrhea.Conclusions:Cabazitaxel and carboplatin followed by abiraterone, together with ADT, were feasible, safe, and efficacious in patients with high-volume mCSPC and warrant further study in larger randomized trials.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study
Figure S1 from Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study
Figure S1 from Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study
Figure S3 from Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study
Figure S3 from Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study
Figure S4 from Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study
Figure S4 from Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study
Figure S2 from Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study
Figure S2 from Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study
- 9 June 2026
- Published by Oxford University Press (OUP) in Nicotine & Tobacco Research
Effects of relighting cigarettes on biomarkers of carcinogen and toxicant exposures
Introduction: Some people who relight cigarettes (extinguishing then relighting later) believe they are reducing health harm from smoking, although studies suggest an increase in health risk compared to those who do not relight. Few studies have evaluated differences in biomarkers of exposures to toxicants among those who relight compared to those who do not. Methods: Secondary analyses were conducted on baseline data from 2 clinical trials. Both studies assessed relighting frequency and collected urine samples. Measures included total nicotine equivalents (TNE), 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol and its glucuronides (total NNAL; lung carcinogen metabolites for 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone[NNK]), 2-cyanoethyl mercapturic acid (CEMA; acrylonitrile metabolite), 3-hydroxy-1-methylpropyl mercapturic acid (HMPMA; crotonaldehyde metabolite), 3-hydroxypropyl mercapturic acid (3-HPMA; acrolein metabolite), and S-phenyl mercapturic acid (SPMA; benzene metabolite). Biomarkers were adjusted for creatinine and calculated per cigarette. Wilcoxon rank-sum tests (unadjusted) and multivariable linear regression (adjusting for variables differing between groups) compared participants who reported relighting cigarettes at least half the time and those who did not report relighting. Results: Relighting participants (n = 94) smoked fewer cigarettes/day than non-relighting participants (n = 181) (13.1 vs 14.9; P = .045) but had higher TNE (P = .047). Other biomarkers did not differ (Ps > .05). In unadjusted analysis, most biomarkers per cigarette were higher for relighting participants (Ps < .021), except total NNAL (P = .159). After covariate adjustment, total NNAL was lower for relighting participants (P = .019), while no per-cigarette biomarkers were significantly different (Ps > .05). Conclusions: People who relight smoke fewer cigarettes but do not reduce exposure to smoke toxicants, possibly due to more intense smoking. However, differences in levels per cigarette observed may primarily reflect individual characteristics, such as age, income, etc, distinguishing relighting from non-relighting participants. Implications: People who relight do not reduce their exposure to key cigarette smoke toxicants and carcinogens even if on average they smoke fewer cigarettes per day. Whether the greater intensity of smoking each cigarette is a result of relighting or the characteristics of the person who relights requires further study. Tobacco surveillance efforts may be enhanced by including assessment of relighting.
- 9 June 2026
- Published by Oxford University Press (OUP) in Nicotine & Tobacco Research
Effects of relighting cigarettes on biomarkers of carcinogen and toxicant exposures
Introduction: Some people who relight cigarettes (extinguishing then relighting later) believe they are reducing health harm from smoking, although studies suggest an increase in health risk compared to those who do not relight. Few studies have evaluated differences in biomarkers of exposures to toxicants among those who relight compared to those who do not. Methods: Secondary analyses were conducted on baseline data from 2 clinical trials. Both studies assessed relighting frequency and collected urine samples. Measures included total nicotine equivalents (TNE), 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol and its glucuronides (total NNAL; lung carcinogen metabolites for 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone[NNK]), 2-cyanoethyl mercapturic acid (CEMA; acrylonitrile metabolite), 3-hydroxy-1-methylpropyl mercapturic acid (HMPMA; crotonaldehyde metabolite), 3-hydroxypropyl mercapturic acid (3-HPMA; acrolein metabolite), and S-phenyl mercapturic acid (SPMA; benzene metabolite). Biomarkers were adjusted for creatinine and calculated per cigarette. Wilcoxon rank-sum tests (unadjusted) and multivariable linear regression (adjusting for variables differing between groups) compared participants who reported relighting cigarettes at least half the time and those who did not report relighting. Results: Relighting participants (n = 94) smoked fewer cigarettes/day than non-relighting participants (n = 181) (13.1 vs 14.9; P = .045) but had higher TNE (P = .047). Other biomarkers did not differ (Ps > .05). In unadjusted analysis, most biomarkers per cigarette were higher for relighting participants (Ps < .021), except total NNAL (P = .159). After covariate adjustment, total NNAL was lower for relighting participants (P = .019), while no per-cigarette biomarkers were significantly different (Ps > .05). Conclusions: People who relight smoke fewer cigarettes but do not reduce exposure to smoke toxicants, possibly due to more intense smoking. However, differences in levels per cigarette observed may primarily reflect individual characteristics, such as age, income, etc, distinguishing relighting from non-relighting participants. Implications: People who relight do not reduce their exposure to key cigarette smoke toxicants and carcinogens even if on average they smoke fewer cigarettes per day. Whether the greater intensity of smoking each cigarette is a result of relighting or the characteristics of the person who relights requires further study. Tobacco surveillance efforts may be enhanced by including assessment of relighting.